BCAB BioAtla Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCAB

Price (delayed)

$3.25

Market cap

$156.31M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.58

Enterprise value

$47.3M

BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. ...

Highlights
BCAB's debt is down by 38% YoY and by 14% QoQ
The company's EPS rose by 6% YoY and by 3% QoQ
The equity has dropped by 61% year-on-year and by 25% since the previous quarter
BioAtla's quick ratio has shrunk by 58% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.bioatla.com
Peers: OMER OMGA

Key stats

What are the main financial stats of BCAB
Market
Shares outstanding
48.1M
Market cap
$156.31M
Enterprise value
$47.3M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.2
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$123.46M
EBITDA
-$122.24M
Free cash flow
-$104.11M
Per share
EPS
-$2.58
Free cash flow per share
-$2.18
Book value per share
$1.47
Revenue per share
$0
TBVPS
$2.5
Balance sheet
Total assets
$119.66M
Total liabilities
$48.99M
Debt
$2.46M
Equity
$70.67M
Working capital
$88.06M
Liquidity
Debt to equity
0.03
Current ratio
4.11
Quick ratio
3.93
Net debt/EBITDA
0.89
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-75.4%
Return on equity
-110.6%
Return on invested capital
N/A
Return on capital employed
-135.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCAB stock price

How has the BioAtla stock price performed over time
Intraday
2.85%
1 week
27.95%
1 month
-12.16%
1 year
-13.1%
YTD
32.11%
QTD
-5.52%

Financial performance

How have BioAtla's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$129.69M
Net income
-$123.46M
Gross margin
N/A
Net margin
N/A
BCAB's operating income is down by 20% YoY
BioAtla's net income has decreased by 16% YoY

Growth

What is BioAtla's growth rate over time

Valuation

What is BioAtla stock price valuation
P/E
N/A
P/B
2.2
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 6% YoY and by 3% QoQ
BCAB's P/B is 100% above its last 4 quarters average of 1.1
The equity has dropped by 61% year-on-year and by 25% since the previous quarter

Efficiency

How efficient is BioAtla business performance
The company's return on equity has shrunk by 76% YoY and by 24% QoQ
BioAtla's ROA has plunged by 52% YoY and by 16% from the previous quarter

Dividends

What is BCAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCAB.

Financial health

How did BioAtla financials performed over time
The company's total assets is 144% higher than its total liabilities
BioAtla's quick ratio has shrunk by 58% YoY
The current ratio has plunged by 57% YoY
BCAB's debt is 97% lower than its equity
The equity has dropped by 61% year-on-year and by 25% since the previous quarter
BioAtla's debt to equity has surged by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.